Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TherapeuticsMD Inc (TXMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: TXMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -74.66% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.11M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 554541 | Beta 1.18 | 52 Weeks Range 0.70 - 2.38 | Updated Date 03/27/2025 |
52 Weeks Range 0.70 - 2.38 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-03-27 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -207.77% | Operating Margin (TTM) -157.04% |
Management Effectiveness
Return on Assets (TTM) -6.65% | Return on Equity (TTM) -14.39% |
Valuation
Trailing PE - | Forward PE 2.29 | Enterprise Value 14462053 | Price to Sales(TTM) 7.59 |
Enterprise Value 14462053 | Price to Sales(TTM) 7.59 | ||
Enterprise Value to Revenue 9.06 | Enterprise Value to EBITDA 14.81 | Shares Outstanding 11532400 | Shares Floating 9474470 |
Shares Outstanding 11532400 | Shares Floating 9474470 | ||
Percent Insiders 1.93 | Percent Institutions 30.61 |
Analyst Ratings
Rating 3 | Target Price 5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TherapeuticsMD Inc
Company Overview
History and Background
TherapeuticsMD, Inc. was founded in 2008. It focused on developing and commercializing products targeting women's health. The company faced financial challenges and ultimately underwent significant restructuring.
Core Business Areas
- Women's Health Products: Focused on developing and commercializing hormone therapy products, including hormone therapy combinations, and prenatal vitamins for women. Key products included ANNOVERA, BIJUVA, and IMVEXXY.
Leadership and Structure
At the time of its acquisition by Mayne Pharma, the leadership included Hugh O'Dowd (CEO). The company had a typical corporate structure with various departments focused on research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- ANNOVERA: A reusable vaginal ring for contraception. Market share data is not readily available; it competed with oral contraceptives and other long-acting reversible contraceptives (LARCs). Competitors included pharmaceutical companies offering birth control pills and IUDs like Bayer (Mirena IUD) and Allergan (Lo Loestrin Fe). Revenue from this product was a key driver for TherapeuticsMD but ultimately insufficient to achieve profitability.
- BIJUVA: A bio-identical hormone therapy combination of estradiol and progesterone for moderate to severe vasomotor symptoms due to menopause. Market share data is not readily available. Competitors included other hormone therapy products from companies like Pfizer and Mylan. Revenue from BIJUVA was expected to contribute significantly to TherapeuticsMD's growth.
- IMVEXXY: A vaginal estrogen therapy for dyspareunia due to menopause. Market share data is not readily available. Competitors included other vaginal estrogen therapies from companies like Novo Nordisk.
Market Dynamics
Industry Overview
The women's health market is driven by factors such as an aging population, increasing awareness of women's health issues, and advancements in hormone therapy. It is a competitive market with established players and evolving treatment options.
Positioning
TherapeuticsMD aimed to position itself as an innovative player in the women's health market by developing differentiated products. However, challenges in commercialization and achieving profitability hindered its competitive position. The overall positioning can be considered weak due to financial problems.
Total Addressable Market (TAM)
The total addressable market for women's health therapies is estimated to be in the billions of dollars annually. TherapeuticsMD aimed to capture a portion of this market with its portfolio of products but faced challenges in achieving significant market penetration.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio targeting women's health needs
- Focus on bio-identical hormone therapies
- Approved products with potential for growth
Weaknesses
- High debt levels
- Inability to achieve profitability
- Limited commercialization capabilities
- Dependence on third-party manufacturers
- History of financial losses
Opportunities
- Expansion into new markets
- Development of new products
- Partnerships and collaborations
- Increasing awareness of women's health issues
Threats
- Competition from established pharmaceutical companies
- Pricing pressures
- Regulatory changes
- Generic competition
- Negative publicity regarding hormone therapy
Competitors and Market Share
Key Competitors
- PFE
- BAYRY
- AGN
Competitive Landscape
TherapeuticsMD faced significant disadvantages compared to its larger, more established competitors. Its smaller size, limited resources, and financial challenges hindered its ability to compete effectively.
Major Acquisitions
TherapeuticsMD acquired by Mayne Pharma
- Year: 2022
- Acquisition Price (USD millions): 0
- Strategic Rationale: Mayne Pharma acquired TherapeuticsMD to expand its women's health portfolio and leverage TherapeuticsMD's products and pipeline. TherapeuticsMD agreed to be acquired due to financial struggles and mounting debt.
Growth Trajectory and Initiatives
Historical Growth: The company experienced initial revenue growth with the launch of its products but struggled to achieve sustained profitability.
Future Projections: Future projections were uncertain due to the company's financial difficulties prior to its acquisition. Mayne Pharma would determine any growth projections.
Recent Initiatives: Recent initiatives included restructuring efforts and attempts to reduce debt. These efforts were ultimately insufficient to prevent the acquisition.
Summary
TherapeuticsMD was a company focused on women's health products, facing significant financial challenges which led to the acquisition by Mayne Pharma. The company had innovative products, but its debt and inability to achieve profitability proved to be insurmountable obstacles. While the portfolio of products showed promise, commercial execution fell short. TherapeuticsMD needed to reduce debt and commercialization challenges to succeed.
Similar Companies
- PFE
- AGN
- BAYRY
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Financial News Articles
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data may be estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TherapeuticsMD Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2003-12-11 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1 | Website https://www.therapeuticsmd.com |
Full time employees 1 | Website https://www.therapeuticsmd.com | ||
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.